darolutamide + androgen deprivation therapy + docetaxel

darolutamide + androgen deprivation therapy + docetaxel is a triplet combination therapy being evaluated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). This specific regimen, investigated in a Phase 2 trial led by investigator Yonghong Li, utilizes darolutamide (a highly potent, non-steroidal androgen receptor antagonist), androgen deprivation therapy (ADT), and a modified low-dose docetaxel (60 mg/m²). Darolutamide, developed by Bayer and Orion, functions by binding with high affinity to the androgen receptor, inhibiting its nuclear translocation and DNA binding. Docetaxel is a taxane that promotes microtubule assembly and inhibits disassembly, leading to mitotic arrest. The study aims to determine if this low-dose docetaxel triplet can maintain therapeutic efficacy, specifically achieving undetectable PSA levels, while minimizing the toxicity associated with standard-dose chemotherapy (75 mg/m²) used in established triplet regimens.

Brand names

NubeqaTaxotere

Other names

Darolutamide + ADT + low-dose docetaxelDarolutamide + ADT Combined with Low-dose Docetaxel